Company Information

  

Address: PO BOX 13628
68 TW ALEXANDER DRIVE 
City: RESEARCH TRIANGLE PARK 
State: NC 
Zip Code: 27709 
Telephone: (919) 636-4530 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of Sodium Thiosulfate ("STS") for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by the shareholders of Fennec at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.29NAN/E
03/2017-0.24NAN/E
12/2016-0.22NAN/E
09/2016-0.18NAN/E
06/2016-0.16NAN/E
03/2016-0.11NAN/E
12/2015-0.06NAN/E
09/20150.13NA15.46

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.02Total Liab/Total Assets0.10
Net Inc/Total Assets-0.70Total Liab/Inv Cap0.11
Net Inc/Inv Cap-0.79Total Liab/Comm Equity0.00
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.01
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.01
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio9.88
Inventory TurnoverNACurrent Ratio9.88
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.15 0.55 0.97 0.45
Operating Income -1.48 -0.77 -1.15 -0.56
Interest Exp NA NA NA NA
Pretax Income -1.60 -0.81 -1.14 -0.50
Other Income -0.12 -0.04 -0.01 0.06
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.60 -0.81 -1.14 -0.50

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 10.23 3.25 3.93 4.54
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 10.26 3.29 3.97 4.58
Net Property, Plant & Equipment NA NA NA NA
Total Assets 10.26 3.29 3.97 4.58
Liabilities        
Accounts Payable 0.39 0.36 0.37 0.32
Debt in Current Liabilities 0.19 0.07 0.03 0.04
Total Current Liabilities 0.58 0.43 0.40 0.36
Long-Term Debt NA NA NA NA
Total Liabilities 0.58 0.43 0.40 0.36
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 82.28 74.52 74.52 74.26
Retained Earnings -116.73 -115.13 -114.32 -113.18
Treasury Stock NA NA NA NA
Total Stockholders' Equity 9.68 2.86 3.57 4.22
Total Liabilities and Stockholders' Equity 10.26 3.29 3.97 4.58

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -0.69 -0.68 -0.61 -0.54
Net Cash Provided by Investing Activities 0.00 0.00 0.00 0.00
Net Cash Provided by Financing Activities 7.67 0.00 0.00 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-5.16--
12/20130.001.84--
12/20140.00-2.18-0.22
12/20150.00-0.66-0.06
12/20160.00-2.79-0.22
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17210.01




Report Date : 10/23/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.